Lucid Genomics is a Berlin-based AI genomics company, spun out of the Max Planck Institute for Molecular Genetics and Charité – Universitätsmedizin Berlin. Our mission is to unlock the full diagnostic potential of the human genome, including the 98% of non-coding DNA that conventional tools leave behind. As long-read sequencing technologies mature, the genomic community is gaining unprecedented access to complex variants that short-read approaches routinely miss. Lucid Genomics is built for this new era. Our AI-powered platform is purpose-built to integrate the rich, multi-layered data that long-read sequencing produces: structural variants, DNA methylation patterns, and tandem repeat expansions, analyzed together, at scale, across the entire genome. By unifying these variant classes in a single interpretive framework, Lucid enables clinicians and researchers to resolve cases that have long remained diagnostically unsolved, particularly in rare disease, where structural and non-coding variants are frequently the underlying cause.
Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com. | Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com. Invitae is a part of Labcorp. | We are a global life sciences and healthcare company harnessing science for human good. Every day, our mission is to improve health and improve lives. | Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at https://www.labcorp.com/infectious-disease.
Kura Biotech
Blikka Genomics, the newest division of Kura Biotech, operates in the fields of DNA sequencing and controlled enzymatic synthesis. Guided by our vision to catalyze multi-omics evolution through smart enzymatic development, and leveraging Cantera, our state-of-the-art protein engineering platform, Blikka develops high-performance products that drive scientific breakthroughs. Blikka Genomics commitment to precision, innovation, and sustainability ensures researchers have the tools they need to achieve significant advancements in precision medicine and genomics. Join us in catalyzing multi-omics evolution through smart enzymatic development.
Isohelix
Isohelix is a manufacturer of innovative and high quality DNA, RNA and Microbiome sampling and purification products including buccal swabs, saliva collection devices and wide range of kits for sample stabilization and extraction. Our products are designed to achieve maximum yields and purity whilst being easy to use and adaptable to manual, high-throughput, and automated applications. We can offer customizable services as well as sampling accessories to ensure you have everything you need for your application.
Golden Helix
About Golden Helix Golden Helix has been delivering industry-leading bioinformatics solutions for over a quarter century with thousands of users worldwide. Golden Helix enables hospitals, testing labs, research institutions, and country-wide genome initiatives to conduct a wide spectrum of clinical tests and facilitate genomic research. With its solutions, Golden Helix users can harness the full potential of genomics to identify the cause of disease, gain diagnostic insights, and improve the efficacy and safety of drug treatments, advancing the quest for personalized medicine.
Genomenon
Genomenon is a leading genomic intelligence company transforming patient care by uncovering the genomic drivers of genetic disease and cancer. By combining the power of AI built on the world’s premier genomic data set with genomic expertise, the company simplifies complex genetic data into actionable insights. Genomenon’s integrated software, data, and services solutions empower clients with advanced patient diagnosis and precision medicine development.
Genomics
Genomics is a precision medicine company accelerating target discovery and clinical development through large-scale genomic insights powered by AI/ML-driven analysis. We were formed in 2014 by four ground-breaking statistical and human geneticists at the University of Oxford. Today, we are collaborating with some of the world’s leading innovators in drug development, enabling them to leverage genomics to de-risk decision making, identify and validate targets, improve trial success rates, and reduce trial time-to-completion. Our cutting-edge solutions support the advancement of groundbreaking therapies, enabling our partners to accelerate the discovery and commercialisation of next-generation treatments. | Genomics is a science-led transatlantic TechBio combining large-scale genetic and health data with proprietary analytics to accelerate drug discovery and advance predictive, preventative healthcare. Spun out of the University of Oxford in 2014 by the world’s top statistical and human geneticists, the company is built on a decade of world-class science and R&D. Its mission is to help people lead longer, healthier lives.
Geneyx Inc.
Geneyx’s mission is to deliver easy-to-use clinical-genetic data management and interpretation that enables hospitals and genetic labs to analyze and interpret NGS genetic reliably data at scale for patient diagnosis and R&D. Today, Geneyx Analysis (GA), our leading solution for DNA analysis and interpretation, services 200+ hospitals and labs in 50+ countries worldwide. Used by thousands of users, over 550K+ samples have already been analyzed.